Bavarian Nordic – Ineffective Cancer Vaccine Masked By Misleading Data: Kerrisdale

Is Bavarian Nordic Dendreon 2.0? Ineffective Cancer Vaccine Masked By Misleading Data by Sahm Adrangi, Kerrisdale Capital

Bavarian Nordic is a $1.3B Danish vaccine-maker whose stock price has recently surged (up 63% YTD) thanks to excitement over its putative prostate cancer treatment, Prostvac-VF, a therapeutic vaccine currently undergoing a Phase III clinical trial. Bavarian Nordic touts its earlier Phase II study of Prostvac as showing  the “most pronounced survival to date in...

What feeling does this article give you?

#hashtags to follow:

Bavarian Nordic [+]    Sahm Adrangi [+]    Kerrisdale Capital [+]    Danish [+]    YTD [+]    Prostvac [+]    Phase III [+]    Phase II [+]   

More #news: